{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:12:11Z","timestamp":1789506731697,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","award":["G064015N"],"award-info":[{"award-number":["G064015N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128915","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:55:31Z","timestamp":1783684531000},"page":"128915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antibody persistence following primary and toddler booster vaccination of a hexavalent DTaP-IPV-HB-PRP\u223cT vaccine and immunogenicity of a school-age aP-containing booster vaccine in term and preterm infants born to women vaccinated with Tdap during pregnancy"],"prefix":"10.1016","volume":"88","author":[{"given":"L.","family":"De Weerdt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Boisnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2026.128915_bb0005","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S1473-3099(17)30390-0","article-title":"An update of the global burden of pertussis in children younger than 5 years: a modelling study","volume":"17","author":"Yeung","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128915_bb0010","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1097\/INF.0000000000001545","article-title":"Risk of pertussis in relation to degree of prematurity in children less than 2 years of age","volume":"36","author":"Riise","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128915_bb0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/archdischild-2016-311802","article-title":"Hospitalisation of preterm infants with pertussis in the context of a maternal vaccination programme in England","volume":"103","author":"Byrne","year":"2018","journal-title":"Arch Dis Child"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128915_bb0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.24608","article-title":"Maternal pertussis immunization and immunoglobulin G levels in early- to late-term and preterm infants","volume":"7","author":"Immink","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128915_bb0025","doi-asserted-by":"crossref","first-page":"ofae717","DOI":"10.1093\/ofid\/ofae717","article-title":"Decay rates of maternal tetanus, diphtheria, and pertussis antibody levels in early and moderate-to-late preterm and term infants at birth and at two months","volume":"12","author":"Immink","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2026.128915_bb0030","first-page":"433","article-title":"Pertussis vaccines: WHO position paper - September 2015","volume":"90","author":"WHO","year":"2015","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.128915_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01282","article-title":"Global perspectives on immunization during pregnancy and priorities for future research and development: an international consensus statement","volume":"11","author":"Abu-Raya","year":"2020","journal-title":"Front Immunol"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2026.128915_bb0040","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1093\/cid\/ciw559","article-title":"Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction","volume":"63","author":"Amirthalingam","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128915_bb0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/cid\/ciu821","article-title":"A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013","volume":"60","author":"Dabrera","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128915_bb0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/QCO.0b013e3283607a58","article-title":"Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants","volume":"26","author":"Lindsey","year":"2013","journal-title":"Curr Opin Infect Dis"},{"issue":"44","key":"10.1016\/j.vaccine.2026.128915_bb0055","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1016\/j.vaccine.2014.08.038","article-title":"The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study","volume":"32","author":"Abu Raya","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128915_bb0060","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3854","article-title":"Pertussis antibody concentrations in infants born prematurely to mothers vaccinated in pregnancy","volume":"138","author":"Kent","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128915_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/cid\/ciab424","article-title":"Pertussis immunization during pregnancy: assessment of the role of maternal antibodies on immune responses in term and preterm-born infants","volume":"74","author":"Maertens","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128915_bb0070","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.vaccine.2022.12.021","article-title":"Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP\u223cT vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy","volume":"41","author":"Maertens","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128915_bb0075","unstructured":"European Centre for Disease Prevention and Control. Vaccine schedules in all countries in the EU\/EEA. Available from: https:\/\/vaccine-schedule.ecdc.europa.eu\/. Accessed 30 June 2026."},{"key":"10.1016\/j.vaccine.2026.128915_bb0080","author":"Centers for Disease Control"},{"key":"10.1016\/j.vaccine.2026.128915_bb0085","author":"Government of Canada"},{"key":"10.1016\/j.vaccine.2026.128915_bb0090","author":"Australian Government Department of Health"},{"key":"10.1016\/j.vaccine.2026.128915_bb0095","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijid.2022.01.045","article-title":"What is the true burden of diphtheria, tetanus, pertussis and poliovirus in children aged 3\u201318 in Asia? A systematic literature review","volume":"117","author":"Nicholson","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128915_bb0100","author":"Argentina Ministry of Health"},{"key":"10.1016\/j.vaccine.2026.128915_bb0105","author":"Ministerio de Salud de Costa Rica"},{"issue":"37","key":"10.1016\/j.vaccine.2026.128915_bb0110","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1016\/j.vaccine.2018.07.048","article-title":"Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines","volume":"36","author":"Itell","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128915_bb0115","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1007\/s40121-021-00530-7","article-title":"A new electrochemiluminescence-based multiplex assay for the assessment of human antibody responses to Bordetella pertussis vaccines","volume":"10","author":"Varghese","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128915_bb0120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/cid\/ciab424","article-title":"Pertussis immunization during pregnancy: assessment of the role of maternal antibodies on immune responses in term and preterm born infants","volume":"74","author":"Maertens","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128915_bb0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1542\/peds.2014-1729","article-title":"Duration of pertussis immunity after DTaP immunization: a meta-analysis","volume":"135","author":"McGirr","year":"2015","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128915_bb0135","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/21645515.2018.1426418","article-title":"Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP\u223cT vaccination at 2, 4 and 6 months","volume":"14","author":"Kosalaraksa","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128915_bb0140","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.vaccine.2009.10.074","article-title":"Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand","volume":"28","author":"Poovorawan","year":"2010","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128915_bb0145","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4161\/hv.24844","article-title":"Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand","volume":"9","author":"Poovorawan","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128915_bb0150","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4161\/hv.19989","article-title":"Persistence and immune memory to hepatitis B vaccine 20 years after primary vaccination of Thai infants, born to HBsAg and HBeAg positive mothers","volume":"8","author":"Poovorawan","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128915_bb0155","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1016\/j.vaccine.2016.04.013","article-title":"Immunity to hepatitis B persists in adolescents 15-16 years of age vaccinated in infancy with three doses of hepatitis B vaccine","volume":"34","author":"Van Der Meeren","year":"2016","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128915_bb0160","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.4161\/hv.28480","article-title":"Immune memory to hepatitis B persists in children aged 7-8 years, who were vaccinated in infancy with 4 doses of hexavalent DTPa-HBV-IPV\/Hib (Infanrix hexa) vaccine","volume":"10","author":"Van Der Meeren","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"27","key":"10.1016\/j.vaccine.2026.128915_bb0165","first-page":"369","article-title":"Hepatitis B vaccines: WHO position paper - July 2017","volume":"92","author":"WHO","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128915_bb0170","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/21645515.2018.1546524","article-title":"Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration","volume":"15","author":"Madhi","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128915_bb0175","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4161\/hv.6.2.10117","article-title":"Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV\/Hib","volume":"6","author":"Zinke","year":"2010","journal-title":"Hum Vaccin"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128915_bb0180","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.4161\/21645515.2014.970494","article-title":"Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV\/Hib at 3, 5, and 11 months of age","volume":"10","author":"Silfverdal","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128915_bb0185","doi-asserted-by":"crossref","first-page":"2352909","DOI":"10.1080\/21645515.2024.2352909","article-title":"Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccines","volume":"20","author":"Wanlapakorn","year":"2024","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128915_bb0190","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1097\/INF.0000000000002954","article-title":"Persistence of hepatitis B immune memory until 6 years of age following hexavalent DTaP-IPV-HB-PRP\u223cT vaccination in a 3-, 5- and 11- to 12-month schedule and response to a subsequent hepatitis B challenge vaccination","volume":"40","author":"Virta","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128915_bb0195","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/INF.0b013e318124a9c8","article-title":"Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely","volume":"26","author":"Omenaca","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2026.128915_bb0200","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1016\/S0264-410X(02)00230-X","article-title":"Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants","volume":"20","author":"Esposito","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128915_bb0205","doi-asserted-by":"crossref","first-page":"1031924","DOI":"10.3389\/fimmu.2022.1031924","article-title":"The adaptive immune system in early life: the shift makes it count","volume":"13","author":"Pieren","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128915_bb0210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nri2075","article-title":"Innate immunity of the newborn: basic mechanisms and clinical correlates","volume":"7","author":"Levy","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128915_bb0215","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jpeds.2009.08.049","article-title":"Accounting for multiple births in neonatal and perinatal trials: systematic review and case study","volume":"156","author":"Hibbs","year":"2010","journal-title":"J Pediatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:48:37Z","timestamp":1789505317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"alternative-id":["S0264410X26007243"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128915","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody persistence following primary and toddler booster vaccination of a hexavalent DTaP-IPV-HB-PRP\u223cT vaccine and immunogenicity of a school-age aP-containing booster vaccine in term and preterm infants born to women vaccinated with Tdap during pregnancy","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128915"}}